Clinical Trials Logo

Filter by:
NCT ID: NCT05431894 Completed - Clinical trials for Cardiovascular Diseases

Behavioral and Recovery Support for 30 Day Post-Discharge Care

Start date: February 18, 2021
Phase: N/A
Study type: Interventional

This study will provide behavioral and mental health support to a select group of participants to supplement the hospital-provided discharge and recovery plans, based on clinical guidance and dedicated post-hospitalization behavioral protocols, with the goals of reducing readmission rates and costs.

NCT ID: NCT05431751 Recruiting - Immune Surveillance Clinical Trials

Clinical Proof-of-concept Study on Immune Surveillance and Alertness

Start date: July 13, 2022
Phase: N/A
Study type: Interventional

Clinical proof-of-concept study comparing the acute. effects of an algae-based dietary supplement on immune surveillance and alertness. This study involves twenty-four participants composed of healthy adults, who will be taking either a placebo or supplement at different times. Testing for immune status, cytokine levels, and immune responsiveness will be conducted to determine the acute impact of the supplement on immune function compared to a placebo. Long term effects and lingering effects will be tested using the same parameters, following a consumption period of one week, as well as a washout period of one week.

NCT ID: NCT05431686 Recruiting - Type 1 Diabetes Clinical Trials

Group Visits for High Risk Type 1 Diabetes (T1D)

Start date: June 2022
Phase: N/A
Study type: Interventional

The investigators propose to conduct a randomized pilot study to assess the impact of shared medical appointments (SMA) visits in underserved youth with poorly controlled type 1 diabetes (T1D). The trial will employ an enrollment visit, SMA visits every 3 months over a 12 month study period, followed by a 6-month observational period to assess feasibility and acceptability of SMA and the impact on glycemic control, self-management skills, and health related quality of life.

NCT ID: NCT05431634 Recruiting - Clinical trials for Safety and Tolerability

Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants

Start date: May 12, 2022
Phase: Phase 1
Study type: Interventional

Multiple Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ESK-001 in Healthy Participants

NCT ID: NCT05431608 Recruiting - Multiple Myeloma Clinical Trials

A Study of MCARH109 and MCARH125 in People With Multiple Myeloma

Start date: June 20, 2022
Phase: Phase 1
Study type: Interventional

A sample of participants' T cells will be sent to a laboratory, where the cells will be made into the study therapy, MCARH109 and MCARH125. Participants will receive either MCARH125 alone or MCARH125 with MCARH109.

NCT ID: NCT05431595 Not yet recruiting - Delirium Clinical Trials

Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy

Start date: December 30, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

To examine the effects of haloperidol, chlorpromazine, valproic acid and placebo, in conjunction with standardized non-pharmacologic interventions, in the first line treatment of agitated delirium in hospitalized patients with cancer. This double-blind, randomized clinical trial aims to provide evidence on various therapeutic options for palliating delirium, thereby reducing delirium-related distress and ultimately alleviating suffering.

NCT ID: NCT05431582 Not yet recruiting - Breast Cancer Clinical Trials

Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors

Start date: December 30, 2022
Phase: Phase 1
Study type: Interventional

Primary Objectives are to determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of ZN-c3 and ZN-c3 and bevacizumab or ZN-c3 and bevacizumab plus pembrolizumab in metastatic CCNE1 amplified and TP53 mutant solid tumors as well to evaluate antitumor activity of ZN-c3 and bevacizumab or ZN-c3 and bevacizumab plus pembrolizumab in metastatic CCNE1 amplified and TP53 mutant solid tumors.

NCT ID: NCT05431556 Recruiting - Pancreas Disease Clinical Trials

Virtual Mind-Body Exercises for People Having Pancreatic Surgery

Start date: June 17, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to find out if it is practical to provide 2 interventions, VMB exercise classes and EUC (pre-recorded self-care videos), during the perioperative period (before and after surgery) to improve health-related outcomes and quality of life for people undergoing a pancreatectomy.

NCT ID: NCT05431543 Recruiting - Presbyopia Clinical Trials

Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia

Start date: July 2022
Phase: Phase 2
Study type: Interventional

To evaluate the safety and effectiveness of Aceclidine/Brimonidine (LNZ101) compared with Aceclidine (LNZ100) and vehicle in the treatment of Presbyopia.

NCT ID: NCT05431478 Not yet recruiting - Refractive Errors Clinical Trials

Clinical Performance of Two Reusable Silicone Hydrogel Contact Lenses

Start date: July 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the clinical performance of two reusable silicone hydrogel contact lenses when worn on a daily wear basis.